No evidence of increased blood clot risk from Covid-19 vaccine: AstraZeneca

So far across the EU and UK, there have been 15 events of deep vein thrombosis and 22 events of pulmonary embolism reported among those given the vaccine, based on the number of cases the company has received as of March 8
Vials of AstraZeneca vaccine. (File photo)
Vials of AstraZeneca vaccine. (File photo)
Updated on Mar 15, 2021 12:19 PM IST
Copy Link

Amid the rising concern over thrombotic (blood clots) events, pharma major AstraZeneca issued a statement on Monday saying a review of 17 million people administered its Coronavirus disease (Covid-19) vaccine suggested it was entirely safe.

“AstraZeneca would like to offer its reassurance on the safety of its Covid-19 vaccine based on clear scientific evidence. Safety is of paramount importance and the company is continually monitoring the safety of its vaccine,” said the company in a statement.

“A careful review of all available safety data of more than 17 million people vaccinated in the European Union (EU) and UK with Covid-19 vaccine of AstraZeneca has shown no evidence of an increased risk of pulmonary embolism, deep vein thrombosis (DVT) or thrombocytopenia, in any defined age group, gender, batch or in any particular country,” it added.

So far across the EU and UK, there have been 15 events of deep vein thrombosis and 22 events of pulmonary embolism reported among those given the vaccine, based on the number of cases the company has received as of March 8. This is much lower than would be expected to occur naturally in a general population of this size and is similar across other licensed Covid-19 vaccines. The monthly safety report will be made public on the European Medicines Agency website in the following week, in line with exceptional transparency measures for Covid-19.

Also Read | Ireland, Netherlands halt AstraZeneca Covid-19 jabs as Italy gets set for curbs

Furthermore, in clinical trials, even though the number of thrombotic events was small, these were lower in the vaccinated group. There has also been no evidence of increased bleeding in over 60,000 participants enrolled.

Chief medical officer of AstraZeneca, Ann Taylor, said: “Around 17 million people in the EU and UK have now received our vaccine, and the number of cases of blood clots reported in this group is lower than the hundreds of cases that would be expected among the general population. The nature of the pandemic has led to increased attention in individual cases and we are going beyond the standard practices for safety monitoring of licensed medicines in reporting vaccine events, to ensure public safety.”

“In terms of quality, there are no confirmed issues related to any batch of our vaccine used across Europe, or the rest of the world. Additional testing has been, and is being conducted by ourselves and independently by European health authorities and none of these re-tests have shown cause for concern. During the production of the vaccine, more than 60 quality tests are conducted by AstraZeneca, its partners and by more than 20 independent testing laboratories. All tests need to meet stringent criteria for quality control and this data is submitted to regulators within each country or region for independent review before any batch can be released to countries,” she said.

SHARE THIS ARTICLE ON
Close Story
SHARE
Story Saved
OPEN APP
×
Saved Articles
My Reads
Sign out
New Delhi 0C
Thursday, October 21, 2021